A Flexible Solution for Pharma Pilot Plant Optimisation
GEA Pharma System’s ConsiGma™ 1 R&D process is designed to allow you to test and develop individual process steps with a minimal amount of product, on small scale equipment, but using the same parameters required on production equipment such as the ConsiGma 25.
Through a collaborative partnership,
GEA Pharma Systems and Perceptive Engineering have developed a “bolt on” software solution that extends the product and process development capabilities of the ConsiGma 1, by adding tools for automated experimental design and advanced data-driven modelling techniques.
Flexible design and real time execution of Design of Experiments studies with integrated sample management
Offline data analysis, pre-treatment and visualisation using PharmaMV Development
Model Development and Maintenance facilities for Multi Variate Analysis
Real Time Quality monitoring and Statistical Process Control
Comprehensive User Configurable Dashboards
If you want to discuss your project or learn how to get more from your process, please get in touch.
Explore how we help our clients get more from their data and processes.
How Can We Help?
Our Clients & Partners
Selection of our clients and key partners we work with to improve process efficiency
Throughout development to manufacturing, data is key to enable rapid response to market demand. The knowledge to enable intelligent decisions and the wisdom to optimise the complete product lifecycle is now at your fingertips. The latest release of PerceptiveAPC v8.0 delivers the next
PD2M May 18-20 2021 Virtual This is the place to explore what pharmaceutical manufacturing will look like in 2030, sharing discussions on new ways to develop medicines. How will Industry 4.0 enable us to respond to market demand, delivering flexible, modular manufacturing and bringing
18-19 May 2021 Virtual Perceptive Engineering - an Applied Materials company - is looking forward to participating in the Bionow Pharma Manufacturing Conference 2021. We will be joining AstraZeneca and Bristol Meyers Squibb in session 2, discussing the ‘Digitisation of Pharma